Leader
|
|
|
00000nz a2200037n 45 0 |
001
|
|
|
WKP|Q6766473
(VIAF cluster)
(Authority/Source Record)
|
003
|
|
|
WKP |
005
|
|
|
20241221010851.0 |
008
|
|
|
241221nneanz||abbn n and d |
035
|
|
|
‡a
(WKP)Q6766473
|
024
|
|
|
‡a
0000-0002-3739-4459
‡2
orcid
|
024
|
|
|
‡a
55574203004
‡2
scopus
|
035
|
|
|
‡a
(OCoLC)Q6766473
|
043
|
|
|
‡c
US
|
046
|
|
|
‡f
19650815
‡g
20101219
|
100
|
0 |
|
‡a
Mark Anthony Smith
‡c
American neuroscientist and Alzheimer researcher (1965-2010)
‡9
en
|
375
|
|
|
‡a
1
‡2
iso5218
|
400
|
0 |
|
‡a
Mark Smith
‡9
sco
‡9
scn
‡9
co
‡9
io
‡9
pms
‡9
vmf
‡9
mi
‡9
sr-el
‡9
an
‡9
cs
‡9
cy
‡9
gd
‡9
ga
‡9
et
‡9
eu
‡9
zu
‡9
gl
‡9
ie
‡9
id
‡9
prg
‡9
en-gb
‡9
lb
‡9
nrm
‡9
nn
‡9
min
‡9
frp
‡9
af
‡9
nap
‡9
lij
‡9
li
‡9
hr
‡9
lt
‡9
jam
‡9
vec
‡9
nds-nl
‡9
vi
‡9
rm
‡9
ro
‡9
ia
‡9
pcd
‡9
frc
‡9
kab
‡9
wa
‡9
wo
‡9
bm
‡9
hu
‡9
sc
‡9
br
‡9
fur
‡9
vls
‡9
vo
‡9
kg
‡9
en-ca
‡9
mg
‡9
bar
‡9
gsw
‡9
oc
‡9
sv
‡9
de-ch
‡9
sk
‡9
pap
‡9
pl
‡9
ms
‡9
de-at
‡9
nds
‡9
rgn
‡9
sw
|
400
|
0 |
|
‡a
Mark A. Smith
‡9
fr
‡9
pt
‡9
ca
‡9
de
‡9
it
‡9
da
‡9
pt-br
‡9
sl
‡9
fi
‡9
nb
|
400
|
0 |
|
‡a
Mark Smith
‡c
araştırmacı
‡9
tr
|
400
|
0 |
|
‡a
Mark Smith
‡c
usona neŭrosciencisto
‡9
eo
|
400
|
0 |
|
‡a
Mark A. Smith
‡c
neurocientífico estadounidense
‡9
es
|
400
|
0 |
|
‡a
Mark A. Smith
‡c
neurocientíficu estauxunidense (1965–2010)
‡9
ast
|
400
|
0 |
|
‡a
মার্ক এ. স্মিথ
‡9
bn
|
400
|
0 |
|
‡a
مارك سميث
‡c
عالم أعصاب من الولايات المتحدة الأمريكية
‡9
ar
|
400
|
0 |
|
‡a
Mark A. Smith
‡c
Amerikaans neurowetenschapper (1965-2010)
‡9
nl
|
400
|
0 |
|
‡a
مارک ای. اسمیت
‡9
fa
|
670
|
|
|
‡a
Author's 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal
|
670
|
|
|
‡a
Author's A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks
|
670
|
|
|
‡a
Author's A metabolic basis for Alzheimer disease
|
670
|
|
|
‡a
Author's A new model of oxidative stress in rat pups
|
670
|
|
|
‡a
Author's A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer's disease
|
670
|
|
|
‡a
Author's A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan
|
670
|
|
|
‡a
Author's A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules
|
670
|
|
|
‡a
Author's A second look into the oxidant mechanisms in Alzheimer's disease
|
670
|
|
|
‡a
Author's A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease
|
670
|
|
|
‡a
Author's Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease
|
670
|
|
|
‡a
Author's Aberrant localization of importin Alpha 1 in hippocampal neurons in Alzheimer disease
|
670
|
|
|
‡a
Author's Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene
|
670
|
|
|
‡a
Author's Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?
|
670
|
|
|
‡a
Author's Abnormal mitochondrial dynamics and neurodegenerative diseases
|
670
|
|
|
‡a
Author's Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease
|
670
|
|
|
‡a
Author's Absence of cellular stress in brain after hypoxia induced by arousal from hibernation in Arctic ground squirrels
|
670
|
|
|
‡a
Author's Accelerated Alpha -synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells
|
670
|
|
|
‡a
Author's Accumulation of intraneuronal amyloid-β is common in normal brain.
|
670
|
|
|
‡a
Author's Activation of Akt by lithium: pro-survival pathways in aging
|
670
|
|
|
‡a
Author's Activation of P38 kinase links π phosphorylation, oxidative stress and cell cycle-related events in Alzheimer disease
|
670
|
|
|
‡a
Author's Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome
|
670
|
|
|
‡a
Author's Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease
|
670
|
|
|
‡a
Author's AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation
|
670
|
|
|
‡a
Author's All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease
|
670
|
|
|
‡a
Author's Altered redox balance in disease: Can we change the new equilibria?
|
670
|
|
|
‡a
Author's Alzheimer disease and the role of free radicals in the pathogenesis of the disease
|
670
|
|
|
‡a
Author's Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species
|
670
|
|
|
‡a
Author's Alzheimer Disease: Oxidative Stress and Compensatory Responses
|
670
|
|
|
‡a
Author's Alzheimer disease pathology as a host response
|
670
|
|
|
‡a
Author's Alzheimer disease, the two-hit hypothesis: an update
|
670
|
|
|
‡a
Author's Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations
|
670
|
|
|
‡a
Author's Alzheimer's Disease: Advances for a New Century
|
670
|
|
|
‡a
Author's Alzheimer's disease: an intracellular movement disorder?
|
670
|
|
|
‡a
Author's Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
|
670
|
|
|
‡a
Author's Alzheimer's disease and the cell cycle
|
670
|
|
|
‡a
Author's Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies
|
670
|
|
|
‡a
Author's Alzheimer's disease: diverse aspects of mitochondrial malfunctioning
|
670
|
|
|
‡a
Author's Alzheimer's disease: the two-hit hypothesis
|
670
|
|
|
‡a
Author's Amyloid-beta: a
|
670
|
|
|
‡a
Author's Amyloid-beta: a (life) preserver for the brain
|
670
|
|
|
‡a
Author's Amyloid-beta: a vascular sealant that protects against hemorrhage?
|
670
|
|
|
‡a
Author's Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain
|
670
|
|
|
‡a
Author's Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons
|
670
|
|
|
‡a
Author's Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?
|
670
|
|
|
‡a
Author's Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression.
|
670
|
|
|
‡a
Author's Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?
|
670
|
|
|
‡a
Author's Amyloid beta: the alternate hypothesis
|
670
|
|
|
‡a
Author's Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!
|
670
|
|
|
‡a
Author's Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain
|
670
|
|
|
‡a
Author's Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain
|
670
|
|
|
‡a
Author's Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?
|
670
|
|
|
‡a
Author's Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway
|
670
|
|
|
‡a
Author's Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies
|
670
|
|
|
‡a
Author's Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis
|
670
|
|
|
‡a
Author's Antigonadotropins: a novel strategy to halt Alzheimer's disease progression
|
670
|
|
|
‡a
Author's Antimicrobial peptide β-defensin-1 expression is upregulated in Alzheimer's brain
|
670
|
|
|
‡a
Author's Antioxidant approaches for the treatment of Alzheimer's disease
|
670
|
|
|
‡a
Author's Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau.
|
670
|
|
|
‡a
Author's Antioxidant therapy in Alzheimer's disease: theory and practice
|
670
|
|
|
‡a
Author's Apoptosis in Alzheimer disease: a mathematical improbability
|
670
|
|
|
‡a
Author's Apoptotic and Oxidative Indicators in Alzheimer's Disease
|
670
|
|
|
‡a
Author's Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?
|
670
|
|
|
‡a
Author's Ascorbate distribution during hibernation is independent of ascorbate redox state
|
670
|
|
|
‡a
Author's Assembly in vitro of tau protein and its implications in Alzheimer's disease.
|
670
|
|
|
‡a
Author's Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease
|
670
|
|
|
‡a
Author's Autophagocytosis of mitochondria is prominent in Alzheimer disease
|
670
|
|
|
‡a
Author's Autophagy in Alzheimer's disease
|
670
|
|
|
‡a
Author's Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease
|
670
|
|
|
‡a
Author's Biomarkers in Alzheimer's disease: past, present and future
|
670
|
|
|
‡a
Author's BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease
|
670
|
|
|
‡a
Author's c-Jun phosphorylation in Alzheimer disease
|
670
|
|
|
‡a
Author's Call for Elan to publish Alzheimer's trial details.
|
670
|
|
|
‡a
Author's Carnosine: a versatile antioxidant and antiglycating agent
|
670
|
|
|
‡a
Author's Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis
|
670
|
|
|
‡a
Author's CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease
|
670
|
|
|
‡a
Author's Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease
|
670
|
|
|
‡a
Author's Cell cycle deregulation in the neurons of Alzheimer's disease
|
670
|
|
|
‡a
Author's Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle.
|
670
|
|
|
‡a
Author's Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure
|
670
|
|
|
‡a
Author's Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease
|
670
|
|
|
‡a
Author's Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death
|
670
|
|
|
‡a
Author's Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis
|
670
|
|
|
‡a
Author's Cerebral hemorrhage and amyloid-beta
|
670
|
|
|
‡a
Author's Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress
|
670
|
|
|
‡a
Author's Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease
|
670
|
|
|
‡a
Author's Chapter 19. Targeting Oxidative Mechanisms in Alzheimer Disease
|
670
|
|
|
‡a
Author's Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease
|
670
|
|
|
‡a
Author's Chitin-like polysaccharides in Alzheimer's disease brains
|
670
|
|
|
‡a
Author's Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers
|
670
|
|
|
‡a
Author's Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis
|
670
|
|
|
‡a
Author's Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease
|
670
|
|
|
‡a
Author's Chronic Leptin Supplementation Ameliorates Pathology and Improves Cognitive Performance in a Transgenic Mouse Model of Alzheimer's Disease
|
670
|
|
|
‡a
Author's Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells
|
670
|
|
|
‡a
Author's Chronological primacy of oxidative stress in Alzheimer disease.
|
670
|
|
|
‡a
Author's Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease
|
670
|
|
|
‡a
Author's Clinical benefit and preservation of flavonols in dark chocolate manufacturing
|
670
|
|
|
‡a
Author's Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells
|
670
|
|
|
‡a
Author's Commentary: "Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" by Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli.
|
670
|
|
|
‡a
Author's Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response
|
670
|
|
|
‡a
Author's Compensatory responses induced by oxidative stress in Alzheimer disease
|
670
|
|
|
‡a
Author's Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease
|
670
|
|
|
‡a
Author's Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity
|
670
|
|
|
‡a
Author's Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta
|
670
|
|
|
‡a
Author's Current approaches in the treatment of Alzheimer's disease
|
670
|
|
|
‡a
Author's Decline in mitochondrial bioenergetics underlies central insulin resistance in streptozocin-induced model of sporadic Alzheimer's disease
|
670
|
|
|
‡a
Author's Dementia and testosterone levels in men.
|
670
|
|
|
‡a
Author's Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease
|
670
|
|
|
‡a
Author's Differential regulation of glutamate receptors in Alzheimer's disease
|
670
|
|
|
‡a
Author's Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease
|
670
|
|
|
‡a
Author's Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study
|
670
|
|
|
‡a
Author's Dissociated Aβ antibody level in newly diagnosed Alzheimer's disease: A population-based study
|
670
|
|
|
‡a
Author's Disturbance in AMP-activated protein kinase
|
670
|
|
|
‡a
Author's Disturbance in AMP-activated protein kinase (AMPK) signaling pathway in Alzheimer's disease
|
670
|
|
|
‡a
Author's Divalent metal transporter, iron, and Parkinson's disease: a pathological relationship.
|
670
|
|
|
‡a
Author's DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease
|
670
|
|
|
‡a
Author's DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells.
|
670
|
|
|
‡a
Author's Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease
|
670
|
|
|
‡a
Author's Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice
|
670
|
|
|
‡a
Author's Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits
|
670
|
|
|
‡a
Author's Drug discovery for neurodegenerative diseases: challenges and novel biochemical targets dedicated to the memory of Mark A. Smith for his inspiring contribution to Alzheimer's disease
|
670
|
|
|
‡a
Author's Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance
|
670
|
|
|
‡a
Author's Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence
|
670
|
|
|
‡a
Author's Early amyloid accumulation in the hippocampus of SAMP8 mice
|
670
|
|
|
‡a
Author's Early induction of c-Myc is associated with neuronal cell death
|
670
|
|
|
‡a
Author's Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity
|
670
|
|
|
‡a
Author's Ectopic expression of phospho-Smad2 in Alzheimer's disease: uncoupling of the transforming growth factor-beta pathway?
|
670
|
|
|
‡a
Author's Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease
|
670
|
|
|
‡a
Author's Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?
|
670
|
|
|
‡a
Author's Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease
|
670
|
|
|
‡a
Author's Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells
|
670
|
|
|
‡a
Author's Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease
|
670
|
|
|
‡a
Author's Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology
|
670
|
|
|
‡a
Author's Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment
|
670
|
|
|
‡a
Author's Emerging evidence for the neuroprotective role of Alpha -synuclein
|
670
|
|
|
‡a
Author's Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis
|
670
|
|
|
‡a
Author's Evidence for Oxidative Damage in the Autistic Brain
|
670
|
|
|
‡a
Author's Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.
|
670
|
|
|
‡a
Author's Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease
|
670
|
|
|
‡a
Author's Evidence for the role of luteinizing hormone in Alzheimer disease
|
670
|
|
|
‡a
Author's Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes
|
670
|
|
|
‡a
Author's Expression of CD74 is increased in neurofibrillary tangles in Alzheimer's disease
|
670
|
|
|
‡a
Author's Feedback on a feedback loop: the hypothalamic-pituitary-gonadal axis.
|
670
|
|
|
‡a
Author's Ferric cycle activity and Alzheimer disease
|
670
|
|
|
‡a
Author's Food Antioxidants and Alzheimer’s Disease
|
670
|
|
|
‡a
Author's Foreword: Apoptotic Mechanisms in Neurodegenerative Diseases
|
670
|
|
|
‡a
Author's Formation of aberrant phosphotau fibrillar polymers in neural cultured cells
|
670
|
|
|
‡a
Author's From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model
|
670
|
|
|
‡a
Author's From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8).
|
670
|
|
|
‡a
Author's Frontiers in Alzheimer's disease therapeutics
|
670
|
|
|
‡a
Author's Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage
|
670
|
|
|
‡a
Author's Gender differences in Alzheimer disease: the role of luteinizing hormone in disease pathogenesis
|
670
|
|
|
‡a
Author's Getting the iron out: phlebotomy for Alzheimer's disease?
|
670
|
|
|
‡a
Author's Gonadotropins: a cohesive gender-based etiology of Alzheimer disease
|
670
|
|
|
‡a
Author's Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
|
670
|
|
|
‡a
Author's Heme-a, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer's disease
|
670
|
|
|
‡a
Author's Heme catabolism and heme oxygenase in neurodegenerative disease
|
670
|
|
|
‡a
Author's Heme deficiency in Alzheimer's disease: a possible connection to porphyria
|
670
|
|
|
‡a
Author's Hibernation, a Model of Neuroprotection
|
670
|
|
|
‡a
Author's High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal
|
670
|
|
|
‡a
Author's Hippocampal neurogenesis and PSA-NCAM expression following exposure to 56Fe particles mimics that seen during aging in rats
|
670
|
|
|
‡a
Author's Homocysteine and Alzheimer's disease: a modifiable risk?
|
670
|
|
|
‡a
Author's Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans
|
670
|
|
|
‡a
Author's Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover
|
670
|
|
|
‡a
Author's Hydroxynonenal, toxic carbonyls, and Alzheimer disease
|
670
|
|
|
‡a
Author's Ill-fated amyloid-beta vaccine
|
670
|
|
|
‡a
Author's Impaired balance of mitochondrial fission and fusion in Alzheimer's disease
|
670
|
|
|
‡a
Author's Increased expression of p130 in Alzheimer disease
|
670
|
|
|
‡a
Author's Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain
|
670
|
|
|
‡a
Author's Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment
|
670
|
|
|
‡a
Author's Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease
|
670
|
|
|
‡a
Author's Increased p27, an essential component of cell cycle control, in Alzheimer's disease
|
670
|
|
|
‡a
Author's Increases in luteinizing hormone are associated with declines in cognitive performance
|
670
|
|
|
‡a
Author's Indices of metabolic dysfunction and oxidative stress
|
670
|
|
|
‡a
Author's Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease
|
670
|
|
|
‡a
Author's Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease
|
670
|
|
|
‡a
Author's Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease
|
670
|
|
|
‡a
Author's Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation
|
670
|
|
|
‡a
Author's Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets
|
670
|
|
|
‡a
Author's Insulin is a two-edged knife on the brain
|
670
|
|
|
‡a
Author's Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?
|
670
|
|
|
‡a
Author's Insulin signaling, diabetes mellitus and risk of Alzheimer disease.
|
670
|
|
|
‡a
Author's Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease
|
670
|
|
|
‡a
Author's Involvement of Maillard reactions in Alzheimer disease
|
670
|
|
|
‡a
Author's Involvement of oxidative stress in Alzheimer disease
|
670
|
|
|
‡a
Author's Iron: A Pathological Mediator of Alzheimer Disease?
|
670
|
|
|
‡a
Author's Iron homeostasis is maintained in the brain, but not the liver, following mild hypoxia
|
670
|
|
|
‡a
Author's Iron: the Redox-active center of oxidative stress in Alzheimer disease
|
670
|
|
|
‡a
Author's Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion
|
670
|
|
|
‡a
Author's Is Alzheimer's disease a mitochondrial disorder?
|
670
|
|
|
‡a
Author's Is Alzheimers Disease a Myth? When is Disease a Disease?
|
670
|
|
|
‡a
Author's Is intraneuronal amyloid beta-peptide accumulation the trigger of Alzheimer's disease pathophysiology?
|
670
|
|
|
‡a
Author's Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?
|
670
|
|
|
‡a
Author's Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?
|
670
|
|
|
‡a
Author's Is the time dimension of the cell cycle re-entry in AD regulated by centromere cohesion dynamics?
|
670
|
|
|
‡a
Author's JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease
|
670
|
|
|
‡a
Author's Klf15 orchestrates circadian nitrogen homeostasis
|
670
|
|
|
‡a
Author's La función del estrés oxidativo en la patogénesis de la enfermedad de Alzheimer
|
670
|
|
|
‡a
Author's Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice
|
670
|
|
|
‡a
Author's Leptin: a novel therapeutic strategy for Alzheimer's disease
|
670
|
|
|
‡a
Author's Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β-amyloid in neurons
|
670
|
|
|
‡a
Author's Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells
|
670
|
|
|
‡a
Author's Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells
|
670
|
|
|
‡a
Author's Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease
|
670
|
|
|
‡a
Author's Leucine-rich repeat kinase 2 colocalizes with Alpha -synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies
|
670
|
|
|
‡a
Author's Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide
|
670
|
|
|
‡a
Author's Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts.
|
670
|
|
|
‡a
Author's Lipoic acid and N-acetyl cysteine protect against mitochondrial-related oxidative stress in fibroblasts from Alzheimer disease patients
|
670
|
|
|
‡a
Author's Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease
|
670
|
|
|
‡a
Author's LRRK2 in Parkinson's disease and dementia with Lewy bodies
|
670
|
|
|
‡a
Author's LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease
|
670
|
|
|
‡a
Author's LRRK2 protein is a component of lewy bodies
|
670
|
|
|
‡a
Author's Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition
|
670
|
|
|
‡a
Author's Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice
|
670
|
|
|
‡a
Author's Malignant glioma progression and nitric oxide
|
670
|
|
|
‡a
Author's MAPKs are differentially modulated in arctic ground squirrels during hibernation
|
670
|
|
|
‡a
Author's Mathematical modeling of microtubule dynamics: insights into physiology and disease
|
670
|
|
|
‡a
Author's Melatonin exhibits antioxidant properties in a mouse brain slice model of excitotoxicity
|
670
|
|
|
‡a
Author's Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease
|
670
|
|
|
‡a
Author's Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease
|
670
|
|
|
‡a
Author's Menopause, estrogen, and gonadotropins in Alzheimer's disease
|
670
|
|
|
‡a
Author's Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence
|
670
|
|
|
‡a
Author's Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease
|
670
|
|
|
‡a
Author's Metal Homeostasis and Its Relation to Oxidative Stress in Alzheimer’s Disease
|
670
|
|
|
‡a
Author's Metal ions and oxidative protein modification in neurological disease.
|
670
|
|
|
‡a
Author's Microbial origin of glutamate, hibernation and tissue trauma: an in vivo microdialysis study
|
670
|
|
|
‡a
Author's Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins
|
670
|
|
|
‡a
Author's Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation
|
670
|
|
|
‡a
Author's Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation
|
670
|
|
|
‡a
Author's Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease
|
670
|
|
|
‡a
Author's Mitochondria: a therapeutic target in neurodegeneration
|
670
|
|
|
‡a
Author's Mitochondria and Neurodegenerative Diseases
|
670
|
|
|
‡a
Author's Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice
|
670
|
|
|
‡a
Author's Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease
|
670
|
|
|
‡a
Author's Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease
|
670
|
|
|
‡a
Author's Mitochondria: the missing link between preconditioning and neuroprotection
|
670
|
|
|
‡a
Author's Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease.
|
670
|
|
|
‡a
Author's Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease.
|
670
|
|
|
‡a
Author's Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease
|
670
|
|
|
‡a
Author's Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease
|
670
|
|
|
‡a
Author's Mitochondrial Drugs for Alzheimer Disease
|
670
|
|
|
‡a
Author's Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies
|
670
|
|
|
‡a
Author's Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology
|
670
|
|
|
‡a
Author's Mitochondrial failures in Alzheimer's disease
|
670
|
|
|
‡a
Author's Mitochondrial importance in Alzheimer's, Huntington's and Parkinson's diseases
|
670
|
|
|
‡a
Author's Mitochondrial preconditioning: a potential neuroprotective strategy
|
670
|
|
|
‡a
Author's Mitogen- and stress-activated protein kinase 1: convergence of the ERK and p38 pathways in Alzheimer's disease
|
670
|
|
|
‡a
Author's Modeling cholesterol metabolism by gene expression profiling in the hippocampus
|
670
|
|
|
‡a
Author's Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment
|
670
|
|
|
‡a
Author's Modification of amyloid-β1-42 fibril structure by methionine-35 oxidation
|
670
|
|
|
‡a
Author's Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats
|
670
|
|
|
‡a
Author's Molecular neuropathogenesis of Alzheimer's disease: an interaction model stressing the central role of oxidative stress
|
670
|
|
|
‡a
Author's Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches
|
670
|
|
|
‡a
Author's Nanoparticle and iron chelators as a potential novel Alzheimer therapy
|
670
|
|
|
‡a
Author's Nanoparticle and other metal chelation therapeutics in Alzheimer disease
|
670
|
|
|
‡a
Author's Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease
|
670
|
|
|
‡a
Author's Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming!
|
670
|
|
|
‡a
Author's Nanoparticle-iron Chelator Conjugates as Multifunctional Disease-modifying Drugs for Prevention and Treatment of Alzheimer’s Disease
|
670
|
|
|
‡a
Author's Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance
|
670
|
|
|
‡a
Author's Natural Oxidant Balance in Parkinson Disease
|
670
|
|
|
‡a
Author's Neurodegenerative diseases: mechanisms and therapies
|
670
|
|
|
‡a
Author's Neurodegenerative processes in Alzheimer’s disease: an overview of pathogenesis with strategic biomarker potential
|
670
|
|
|
‡a
Author's Neuroendocrinology-based therapy for Alzheimer's disease
|
670
|
|
|
‡a
Author's Neurofibrillary Tangle Formation as a Protective Response to Oxidative Stress in Alzheimer’s Disease
|
670
|
|
|
‡a
Author's Neurofilamentopathy in neurodegenerative diseases
|
670
|
|
|
‡a
Author's Neurogenesis in Alzheimer’s Disease
|
670
|
|
|
‡a
Author's Neurogenesis in Human Hippocampus: Implications for Alzheimer Disease Pathogenesis
|
670
|
|
|
‡a
Author's Neuronal cell cycle re-entry markers are altered in the senescence accelerated mouse P8
|
670
|
|
|
‡a
Author's Neuronal cell cycle re-entry markers are altered in the senescence accelerated mouse P8 (SAMP8).
|
670
|
|
|
‡a
Author's Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass
|
670
|
|
|
‡a
Author's Neuronal leptin resistance in Alzheimer's disease
|
670
|
|
|
‡a
Author's Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats
|
670
|
|
|
‡a
Author's Neuronal RNA oxidation is a prominent feature of dementia with Lewy bodies
|
670
|
|
|
‡a
Author's Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease
|
670
|
|
|
‡a
Author's Neuronal Survival and Death in Alzheimer Disease
|
670
|
|
|
‡a
Author's Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
|
670
|
|
|
‡a
Author's Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream
|
670
|
|
|
‡a
Author's Neuropathology of Alzheimer disease: pathognomonic but not pathogenic
|
670
|
|
|
‡a
Author's Neuroprotective effect of cocoa flavonoids on in vitro oxidative stress
|
670
|
|
|
‡a
Author's Neuroprotective effects of caffeine against complex I inhibition-induced apoptosis are mediated by inhibition of the Atm/p53/E2F-1 path in cerebellar granule neurons
|
670
|
|
|
‡a
Author's Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons
|
670
|
|
|
‡a
Author's Neuroprotective properties of Bcl-w in Alzheimer disease
|
670
|
|
|
‡a
Author's Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers
|
670
|
|
|
‡a
Author's New insights into the mechanisms of mitochondrial preconditioning-triggered neuroprotection
|
670
|
|
|
‡a
Author's NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion comple xing site of amyloid-beta peptide
|
670
|
|
|
‡a
Author's Novel therapeutics for Alzheimer's disease: an update
|
670
|
|
|
‡a
Author's Nuclear and mitochondrial DNA oxidation in Alzheimer's disease
|
670
|
|
|
‡a
Author's Nucleic acid oxidation in Alzheimer disease
|
670
|
|
|
‡a
Author's O2-04-07 Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1 associated regulator of cyclin B, in Alzheimer disease
|
670
|
|
|
‡a
Author's Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions
|
670
|
|
|
‡a
Author's Oxidative damage and Alzheimer's disease: are antioxidant therapies useful?
|
670
|
|
|
‡a
Author's Oxidative Damage and Antioxidant Responses in Alzheimer's Disease
|
670
|
|
|
‡a
Author's Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients
|
670
|
|
|
‡a
Author's Oxidative damage in the olfactory system in Alzheimer's disease
|
670
|
|
|
‡a
Author's Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis
|
670
|
|
|
‡a
Author's Oxidative damage to nucleic acids in human prion disease
|
670
|
|
|
‡a
Author's Oxidative damage to RNA in aging and neurodegenerative disorders
|
670
|
|
|
‡a
Author's Oxidative damage to RNA in neurodegenerative diseases
|
670
|
|
|
‡a
Author's Oxidative imbalance in Alzheimer's disease
|
670
|
|
|
‡a
Author's Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein
|
670
|
|
|
‡a
Author's Oxidative Stress and Alzheimer Disease: Mechanisms and Therapeutic Opportunities
|
670
|
|
|
‡a
Author's Oxidative Stress and Balance in Neurodegenerative Diseases
|
670
|
|
|
‡a
Author's Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss!
|
670
|
|
|
‡a
Author's Oxidative Stress and its Implications for Future Treatments and Management of Alzheimer Disease
|
670
|
|
|
‡a
Author's Oxidative stress and neurodegeneration
|
670
|
|
|
‡a
Author's Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy
|
670
|
|
|
‡a
Author's Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways
|
670
|
|
|
‡a
Author's Oxidative stress and neurotoxicity
|
670
|
|
|
‡a
Author's Oxidative stress and redox-active iron in Alzheimer's disease
|
670
|
|
|
‡a
Author's Oxidative stress in Alzheimer disease: a possibility for prevention
|
670
|
|
|
‡a
Author's Oxidative Stress in Alzheimer’s Disease: A Critical Appraisal of the Causes and the Consequences
|
670
|
|
|
‡a
Author's Oxidative stress in diabetes and Alzheimer's disease
|
670
|
|
|
‡a
Author's Oxidative Stress in Parkinson`s Disease
|
670
|
|
|
‡a
Author's Oxidative stress increases expression and activity of BACE in NT2 neurons
|
670
|
|
|
‡a
Author's Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage
|
670
|
|
|
‡a
Author's Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease
|
670
|
|
|
‡a
Author's Oxidative stress signalling in Alzheimer's disease
|
670
|
|
|
‡a
Author's Oxidative stress: the old enemy in Alzheimer's disease pathophysiology
|
670
|
|
|
‡a
Author's P1-266 The critical role of the ERK pathway in the pathogenesis of Alzheimer's disease
|
670
|
|
|
‡a
Author's P1-351: A novel approach to diagnosis: Antigen-antibody disassociation in Alzheimer's disease
|
670
|
|
|
‡a
Author's P3-219 Acetylation: a novel posttranslational modification in Alzheimer disease
|
670
|
|
|
‡a
Author's P3-306 Differential expression of metabotrophic glutamate receptors
|
670
|
|
|
‡a
Author's P3-306 Differential expression of metabotrophic glutamate receptors (MGlurs) in Alzheimer disease
|
670
|
|
|
‡a
Author's P3-317: Failure in the control of cell cycle causes neurodegeneration
|
670
|
|
|
‡a
Author's P3-375
|
670
|
|
|
‡a
Author's P38 activation mediates amyloid-beta cytotoxicity
|
670
|
|
|
‡a
Author's P4-162
|
670
|
|
|
‡a
Author's P4-166: Overexpression of amyloid precursor protein causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins
|
670
|
|
|
‡a
Author's Paraffin-embedded tissue
|
670
|
|
|
‡a
Author's Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease
|
670
|
|
|
‡a
Author's Pathological implications of cell cycle re-entry in Alzheimer disease
|
670
|
|
|
‡a
Author's Pathology's new role: defining disease process and protective responses.
|
670
|
|
|
‡a
Author's Perspectives on the amyloid-beta cascade hypothesis
|
670
|
|
|
‡a
Author's Perspectives on the Amyloid-β Cascade Hypothesis
|
670
|
|
|
‡a
Author's Phosphorylated tau: toxic, protective, or none of the above
|
670
|
|
|
‡a
Author's Physiological regulation of tau phosphorylation during hibernation
|
670
|
|
|
‡a
Author's PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562.
|
670
|
|
|
‡a
Author's Possible involvement of Wiskott-Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease
|
670
|
|
|
‡a
Author's Predicting the failure of amyloid-beta vaccine.
|
670
|
|
|
‡a
Author's Premature centromere division of metaphase chromosomes in peripheral blood lymphocytes of Alzheimer's disease patients: relation to gender and age.
|
670
|
|
|
‡a
Author's Premature centromere division of the X chromosome in neurons in Alzheimer's disease
|
670
|
|
|
‡a
Author's Presenilin 1 overexpressions in Chinese hamster ovary
|
670
|
|
|
‡a
Author's Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
|
670
|
|
|
‡a
Author's Presenilin mutation: a deadly first hit in Alzheimer disease. A commentary on "aging sensitizes towards ROS formation and lipid peroxidation in PS1M146L transgenic mice".
|
670
|
|
|
‡a
Author's Prevention and treatment of Alzheimer disease and aging: antioxidants
|
670
|
|
|
‡a
Author's Prion disease and Alzheimer's disease: pathogenic overlap
|
670
|
|
|
‡a
Author's Protein Misfolding in Alzheimer's Disease
|
670
|
|
|
‡a
Author's Protein modification by dicarbonyl molecular species in neurodegenerative diseases
|
670
|
|
|
‡a
Author's Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism
|
670
|
|
|
‡a
Author's R-_-Lipoic Acid as a Potent Agent of Mitochondrial Protectionin Alzheimer’s Disease
|
670
|
|
|
‡a
Author's Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
|
670
|
|
|
‡a
Author's Redox metals and oxidative abnormalities in human prion diseases
|
670
|
|
|
‡a
Author's Reduced homocysteine-thiolactonase activity in Alzheimer's disease
|
670
|
|
|
‡a
Author's Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants
|
670
|
|
|
‡a
Author's Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta
|
670
|
|
|
‡a
Author's Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells
|
670
|
|
|
‡a
Author's Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection
|
670
|
|
|
‡a
Author's Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease.
|
670
|
|
|
‡a
Author's Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron
|
670
|
|
|
‡a
Author's RNA oxidation in Alzheimer disease and related neurodegenerative disorders
|
670
|
|
|
‡a
Author's Role of high mobility group protein-1
|
670
|
|
|
‡a
Author's Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis
|
670
|
|
|
‡a
Author's Role of metal dyshomeostasis in Alzheimer's disease
|
670
|
|
|
‡a
Author's Role of mitochondrial dysfunction in Alzheimer's disease
|
670
|
|
|
‡a
Author's Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia
|
670
|
|
|
‡a
Author's Role of Oxidative Insult and Neuronal Survival in Alzheimer’s and Parkinson’s Diseases
|
670
|
|
|
‡a
Author's Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease
|
670
|
|
|
‡a
Author's S4-02-01 Alzheimer disease: the two hit hypothesis
|
670
|
|
|
‡a
Author's Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins
|
670
|
|
|
‡a
Author's Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy
|
670
|
|
|
‡a
Author's Signal transduction cascades associated with oxidative stress in Alzheimer's disease
|
670
|
|
|
‡a
Author's Signal Transduction in Alzheimer’s Disease
|
670
|
|
|
‡a
Author's Signaling effect of amyloid-beta(42) on the processing of AbetaPP
|
670
|
|
|
‡a
Author's Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations.
|
670
|
|
|
‡a
Author's Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid
|
670
|
|
|
‡a
Author's Staying connected: synapses in Alzheimer disease
|
670
|
|
|
‡a
Author's Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease
|
670
|
|
|
‡a
Author's Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta
|
670
|
|
|
‡a
Author's Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35).
|
670
|
|
|
‡a
Author's Sublethal RNA oxidation as a mechanism for neurodegenerative disease
|
670
|
|
|
‡a
Author's Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy
|
670
|
|
|
‡a
Author's Targeting gonadotropins: an alternative option for Alzheimer disease treatment
|
670
|
|
|
‡a
Author's Tau--an inhibitor of deacetylase HDAC6 function
|
670
|
|
|
‡a
Author's Tau modifiers as therapeutic targets for Alzheimer's disease
|
670
|
|
|
‡a
Author's Tau phosphorylation and assembly.
|
670
|
|
|
‡a
Author's Tau phosphorylation in Alzheimer's disease: pathogen or protector?
|
670
|
|
|
‡a
Author's Telomeres and telomerase in Alzheimer's disease: epiphenomena or a new focus for therapeutic strategy?
|
670
|
|
|
‡a
Author's Temporal Primacy of Oxidative Stress in the Pathological Cascade of Alzheimer Disease
|
670
|
|
|
‡a
Author's The application of microarray technology to neuropathology: cutting edge tool with clinical diagnostics potential or too much information?
|
670
|
|
|
‡a
Author's The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery
|
670
|
|
|
‡a
Author's The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target
|
670
|
|
|
‡a
Author's The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development
|
670
|
|
|
‡a
Author's The cell cycle in Alzheimer disease: a unique target for neuropharmacology
|
670
|
|
|
‡a
Author's The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies
|
670
|
|
|
‡a
Author's The contribution of luteinizing hormone to Alzheimer disease pathogenesis
|
670
|
|
|
‡a
Author's The "Down's" side of mitochondria
|
670
|
|
|
‡a
Author's The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons
|
670
|
|
|
‡a
Author's The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival
|
670
|
|
|
‡a
Author's The essential role of ERK in 4-oxo-2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells
|
670
|
|
|
‡a
Author's The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease
|
670
|
|
|
‡a
Author's The fallacy of amyloid and cognition in Alzheimer's disease
|
670
|
|
|
‡a
Author's The gonadotropin connection in Alzheimer's disease
|
670
|
|
|
‡a
Author's The Key Role of Oxidative Stress in Alzheimer's Disease
|
670
|
|
|
‡a
Author's The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention
|
670
|
|
|
‡a
Author's The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse
|
670
|
|
|
‡a
Author's The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors
|
670
|
|
|
‡a
Author's The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau.
|
670
|
|
|
‡a
Author's The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics
|
670
|
|
|
‡a
Author's The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease
|
670
|
|
|
‡a
Author's The role of E2F1 in the development of hypertrophic cardiomyopathy
|
670
|
|
|
‡a
Author's The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications
|
670
|
|
|
‡a
Author's The role of mitogen-activated protein kinase pathways in Alzheimer's disease
|
670
|
|
|
‡a
Author's The role of novel chitin-like polysaccharides in Alzheimer disease
|
670
|
|
|
‡a
Author's The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease
|
670
|
|
|
‡a
Author's The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations
|
670
|
|
|
‡a
Author's The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease
|
670
|
|
|
‡a
Author's The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease
|
670
|
|
|
‡a
Author's The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1 Alpha
|
670
|
|
|
‡a
Author's The X-chromosome instability phenotype in Alzheimer's disease: a clinical sign of accelerating aging?
|
670
|
|
|
‡a
Author's Therapeutic opportunities in Alzheimer disease: one for all or all for one?
|
670
|
|
|
‡a
Author's Therapeutic options in Alzheimer's disease
|
670
|
|
|
‡a
Author's Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy
|
670
|
|
|
‡a
Author's Therapeutic potential of oxidant mechanisms in Alzheimer's disease
|
670
|
|
|
‡a
Author's Thinking Outside the Box in Alzheimer Disease Treatment
|
670
|
|
|
‡a
Author's Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material
|
670
|
|
|
‡a
Author's Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron
|
670
|
|
|
‡a
Author's Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept
|
670
|
|
|
‡a
Author's Transgenic Mouse Models of Alzheimer's Disease
|
670
|
|
|
‡a
Author's Treating the lesions, not the disease
|
670
|
|
|
‡a
Author's Treatment advances in Alzheimer's disease based on the oxidative stress model
|
670
|
|
|
‡a
Author's Two Hits and You’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease
|
670
|
|
|
‡a
Author's Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide
|
670
|
|
|
‡a
Author's Vascular oxidative stress in Alzheimer disease
|
670
|
|
|
‡a
Author's Widespread distribution of reticulon-3 in various neurodegenerative diseases
|
670
|
|
|
‡a
Author's Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/NUKAT|n 2005130959
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/ISNI|0000000019415688
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/BNF|15021893
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/viaf/328144783016890843210
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/LC|n 2013031838
|
670
|
|
|
‡a
wikidata site links
‡u
https://en.wikipedia.org/wiki/Mark_A._Smith
|
909
|
|
|
‡a
(orcid) 0000000237394459
‡9
1
|
909
|
|
|
‡a
(scopus) 55574203004
‡9
1
|
919
|
|
|
‡a
oxidativestressandneurodegeneration
‡A
Oxidative stress and neurodegeneration
‡9
1
|
919
|
|
|
‡a
oxidativestressandneurodegenerationaninevitableconsequenceofagingimplicationsfortherapy
‡A
Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy
‡9
1
|
919
|
|
|
‡a
oxidativestressandneuronaladaptationinalzheimerdiseasetheroleofsapkpathways
‡A
Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways
‡9
1
|
919
|
|
|
‡a
oxidativestressandneurotoxicity
‡A
Oxidative stress and neurotoxicity
‡9
1
|
919
|
|
|
‡a
oxidativestressandredoxactiveironinalzheimersdisease
‡A
Oxidative stress and redox-active iron in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
oxidativestressinalzheimerdiseaseapossibilityforprevention
‡A
Oxidative stress in Alzheimer disease: a possibility for prevention
‡9
1
|
919
|
|
|
‡a
oxidativestressinalzheimersdiseaseacriticalappraisalofthecausesandtheconsequences
‡A
Oxidative Stress in Alzheimer’s Disease: A Critical Appraisal of the Causes and the Consequences
‡9
1
|
919
|
|
|
‡a
oxidativestressindiabetesandalzheimersdisease
‡A
Oxidative stress in diabetes and Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
oxidativestressinparkinsonsdisease
‡A
Oxidative Stress in Parkinson`s Disease
‡9
1
|
919
|
|
|
‡a
oxidativestressincreasesexpressionandactivityofbaceinnt2neurons
‡A
Oxidative stress increases expression and activity of BACE in NT2 neurons
‡9
1
|
919
|
|
|
‡a
oxidativestressisanearlyeventinhydrostaticpressureinducedretinalganglioncelldamage
‡A
Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage
‡9
1
|
919
|
|
|
‡a
oxidativestressmechanismsandpotentialtherapeuticmodalitiesinalzheimerdisease
‡A
Oxidative Stress Mechanisms and Potential Therapeutic Modalities in Alzheimer Disease
‡9
1
|
919
|
|
|
‡a
oxidativestresssignallinginalzheimersdisease
‡A
Oxidative stress signalling in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
oxidativestresstheoldenemyinalzheimersdiseasepathophysiology
‡A
Oxidative stress: the old enemy in Alzheimer's disease pathophysiology
‡9
1
|
919
|
|
|
‡a
p1266thecriticalroleoftheerkpathwayinthepathogenesisofalzheimersdisease
‡A
P1-266 The critical role of the ERK pathway in the pathogenesis of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
p1351anovelapproachtodiagnosisantigenantibodydisassociationinalzheimersdisease
‡A
P1-351: A novel approach to diagnosis: Antigen-antibody disassociation in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
p3219acetylationanovelposttranslationalmodificationinalzheimerdisease
‡A
P3-219 Acetylation: a novel posttranslational modification in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
p3306differentialexpressionofmetabotrophicglutamatereceptors
‡A
P3-306 Differential expression of metabotrophic glutamate receptors
‡9
1
|
919
|
|
|
‡a
p3306differentialexpressionofmetabotrophicglutamatereceptorsmglursinalzheimerdisease
‡A
P3-306 Differential expression of metabotrophic glutamate receptors (MGlurs) in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
p3317failureinthecontrolofcellcyclecausesneurodegeneration
‡A
P3-317: Failure in the control of cell cycle causes neurodegeneration
‡9
1
|
919
|
|
|
‡a
p3375
‡A
P3-375
‡9
1
|
919
|
|
|
‡a
p38activationmediatesamyloidbetacytotoxicity
‡A
P38 activation mediates amyloid-beta cytotoxicity
‡9
1
|
919
|
|
|
‡a
p4162
‡A
P4-162
‡9
1
|
919
|
|
|
‡a
p4166overexpressionofamyloidprecursorproteincausesabnormalmitochondrialdynamicsviadifferentialmodulationofmitochondrialfissionfusionproteins
‡A
P4-166: Overexpression of amyloid precursor protein causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins
‡9
1
|
919
|
|
|
‡a
paraffinembeddedtissue
‡A
Paraffin-embedded tissue
‡9
1
|
919
|
|
|
‡a
paraffinembeddedtissuepetblotmethodapplicationtoalzheimerdisease
‡A
Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease
‡9
1
|
919
|
|
|
‡a
pathologicalimplicationsofcellcyclereentryinalzheimerdisease
‡A
Pathological implications of cell cycle re-entry in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
pathologysnewroledefiningdiseaseprocessandprotectiveresponses
‡A
Pathology's new role: defining disease process and protective responses.
‡9
1
|
919
|
|
|
‡a
perspectivesontheamyloidbetacascadehypothesis
‡A
Perspectives on the amyloid-beta cascade hypothesis
‡9
1
|
919
|
|
|
‡a
perspectivesontheamyloidβcascadehypothesis
‡A
Perspectives on the Amyloid-β Cascade Hypothesis
‡9
1
|
919
|
|
|
‡a
phosphorylatedtautoxicprotectiveornoneoftheabove
‡A
Phosphorylated tau: toxic, protective, or none of the above
‡9
1
|
919
|
|
|
‡a
physiologicalregulationoftauphosphorylationduringhibernation
‡A
Physiological regulation of tau phosphorylation during hibernation
‡9
1
|
919
|
|
|
‡a
pkcinhibitionisinvolvedintrichosanthininducedapoptosisinhumanchronicmyeloidleukemiacelllinek562
‡A
PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562.
‡9
1
|
919
|
|
|
‡a
possibleinvolvementofwiskottaldrichsyndromeproteinfamilyinaberrantneuronalsproutinginalzheimersdisease
‡A
Possible involvement of Wiskott-Aldrich syndrome protein family in aberrant neuronal sprouting in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
predictingthefailureofamyloidbetavaccine
‡A
Predicting the failure of amyloid-beta vaccine.
‡9
1
|
919
|
|
|
‡a
prematurecentromeredivisionofmetaphasechromosomesinperipheralbloodlymphocytesofalzheimersdiseasepatientsrelationtogenderandage
‡A
Premature centromere division of metaphase chromosomes in peripheral blood lymphocytes of Alzheimer's disease patients: relation to gender and age.
‡9
1
|
919
|
|
|
‡a
prematurecentromeredivisionofthe10chromosomeinneuronsinalzheimersdisease
‡A
Premature centromere division of the X chromosome in neurons in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
presenilin1overexpressionsinchinesehamsterovary
‡A
Presenilin 1 overexpressions in Chinese hamster ovary
‡9
1
|
919
|
|
|
‡a
presenilin1overexpressionsinchinesehamsterovarychocellsdecreasesthephosphorylationofretinoblastomaproteinrelevanceforneurodegeneration
‡A
Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration.
‡9
1
|
919
|
|
|
‡a
presenilinmutationadeadly1hitinalzheimerdiseaseacommentaryonagingsensitizestowardsrosformationandlipidperoxidationinps1m146ltransgenicmice
‡A
Presenilin mutation: a deadly first hit in Alzheimer disease. A commentary on "aging sensitizes towards ROS formation and lipid peroxidation in PS1M146L transgenic mice".
‡9
1
|
919
|
|
|
‡a
preventionandtreatmentofalzheimerdiseaseandagingantioxidants
‡A
Prevention and treatment of Alzheimer disease and aging: antioxidants
‡9
1
|
919
|
|
|
‡a
priondiseaseandalzheimersdiseasepathogenicoverlap
‡A
Prion disease and Alzheimer's disease: pathogenic overlap
‡9
1
|
919
|
|
|
‡a
proteinmisfoldinginalzheimersdisease
‡A
Protein Misfolding in Alzheimer's Disease
‡9
1
|
919
|
|
|
‡a
proteinmodificationbydicarbonylmolecularspeciesinneurodegenerativediseases
‡A
Protein modification by dicarbonyl molecular species in neurodegenerative diseases
‡9
1
|
919
|
|
|
‡a
protonmagneticresonanceimagingandspectroscopyidentifymetabolicchangesinthestriatuminthemptpfelinemodelofparkinsonism
‡A
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism
‡9
1
|
919
|
|
|
‡a
rlipoicacidasapotentagentofmitochondrialprotectioninalzheimersdisease
‡A
R-_-Lipoic Acid as a Potent Agent of Mitochondrial Protectionin Alzheimer’s Disease
‡9
1
|
919
|
|
|
‡a
redoxactiveironatthecenterofoxidativestressinalzheimerdisease
‡A
Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
‡9
1
|
919
|
|
|
‡a
redoxmetalsandoxidativeabnormalitiesinhumanpriondiseases
‡A
Redox metals and oxidative abnormalities in human prion diseases
‡9
1
|
919
|
|
|
‡a
reducedhomocysteinethiolactonaseactivityinalzheimersdisease
‡A
Reduced homocysteine-thiolactonase activity in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
reductionofinclusionbodypathologyinapoedeficientmicefedacombinationofantioxidants
‡A
Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants
‡9
1
|
919
|
|
|
‡a
reexaminingalzheimersdiseaseevidenceforaprotectiveroleforamyloidbetaproteinprecursorandamyloidbeta
‡A
Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta
‡9
1
|
919
|
|
|
‡a
regulationofglycogensynthasekinase3betabyproductsoflipidperoxidationinhumanneuroblastomacells
‡A
Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells
‡9
1
|
919
|
|
|
‡a
resveratrolandneurodegenerativediseasesactivationofsirt1asthepotentialpathwaytowardsneuroprotection
‡A
Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection
‡9
1
|
919
|
|
|
‡a
retinoblastomaproteinphosphorylationatmultiplesitesisassociatedwithneurofibrillarypathologyinalzheimerdisease
‡A
Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease.
‡9
1
|
919
|
|
|
‡a
ribosomalrnainalzheimerdiseaseisoxidizedbyboundredoxactiveiron
‡A
Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron
‡9
1
|
919
|
|
|
‡a
rnaoxidationinalzheimerdiseaseandrelatedneurodegenerativedisorders
‡A
RNA oxidation in Alzheimer disease and related neurodegenerative disorders
‡9
1
|
919
|
|
|
‡a
roleofhighmobilitygroupprotein1
‡A
Role of high mobility group protein-1
‡9
1
|
919
|
|
|
‡a
roleofhighmobilitygroupprotein1hmg1inamyloidbetahomeostasis
‡A
Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis
‡9
1
|
919
|
|
|
‡a
roleofmetaldyshomeostasisinalzheimersdisease
‡A
Role of metal dyshomeostasis in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
roleofmitochondrialdysfunctioninalzheimersdisease
‡A
Role of mitochondrial dysfunction in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
roleofmitochondrialmediatedsignalingpathwaysinalzheimerdiseaseandhypoxia
‡A
Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia
‡9
1
|
919
|
|
|
‡a
roleofoxidativeinsultandneuronalsurvivalinalzheimersandparkinsonsdiseases
‡A
Role of Oxidative Insult and Neuronal Survival in Alzheimer’s and Parkinson’s Diseases
‡9
1
|
919
|
|
|
‡a
roleofvascularhypoperfusioninducedoxidativestressandmitochondriafailureinthepathogenesisofazheimerdisease
‡A
Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease
‡9
1
|
919
|
|
|
‡a
s40201alzheimerdiseasethe2hithypothesis
‡A
S4-02-01 Alzheimer disease: the two hit hypothesis
‡9
1
|
919
|
|
|
‡a
senileplaquecompositionandposttranslationalmodificationofamyloidbetapeptideandassociatedproteins
‡A
Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins
‡9
1
|
919
|
|
|
‡a
sequestrationofp27withinthecytoplasmofcardiacmyocytesinchronicischemicheartdiseasepathogenicimplicationsforischemiccardiomyopathy
‡A
Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy
‡9
1
|
919
|
|
|
‡a
signaltransductioncascadesassociatedwithoxidativestressinalzheimersdisease
‡A
Signal transduction cascades associated with oxidative stress in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
signaltransductioninalzheimersdisease
‡A
Signal Transduction in Alzheimer’s Disease
‡9
1
|
919
|
|
|
‡a
signalingeffectofamyloidbeta42ontheprocessingofabetapp
‡A
Signaling effect of amyloid-beta(42) on the processing of AbetaPP
‡9
1
|
919
|
|
|
‡a
solubleamyloidbetaproteinisincreasedinfrontotemporaldementiawithtaugenemutations
‡A
Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations.
‡9
1
|
919
|
|
|
‡a
specificreactionofmet35inamyloidbetapeptidewithhypochlorousacid
‡A
Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid
‡9
1
|
919
|
|
|
‡a
stayingconnectedsynapsesinalzheimerdisease
‡A
Staying connected: synapses in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
steroidogenicacuteregulatoryproteinstarevidenceofgonadotropininducedsteroidogenesisinalzheimerdisease
‡A
Steroidogenic acute regulatory protein (StAR): evidence of gonadotropin-induced steroidogenesis in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
subcellularandmetabolicexaminationofamyloidbetapeptidesinalzheimerdiseasepathogenesisevidenceforabeta
‡A
Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta
‡9
1
|
919
|
|
|
‡a
subcellularandmetabolicexaminationofamyloidbetapeptidesinalzheimerdiseasepathogenesisevidenceforabeta2535
‡A
Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35).
‡9
1
|
919
|
|
|
‡a
sublethalrnaoxidationasamechanismforneurodegenerativedisease
‡A
Sublethal RNA oxidation as a mechanism for neurodegenerative disease
‡9
1
|
919
|
|
|
‡a
systemicincreaseofoxidativenucleicaciddamageinparkinsonsdiseaseandmultiplesystematrophy
‡A
Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy
‡9
1
|
919
|
|
|
‡a
targetinggonadotropinsanalternativeoptionforalzheimerdiseasetreatment
‡A
Targeting gonadotropins: an alternative option for Alzheimer disease treatment
‡9
1
|
919
|
|
|
‡a
tauaninhibitorofdeacetylasehdac6function
‡A
Tau--an inhibitor of deacetylase HDAC6 function
‡9
1
|
919
|
|
|
‡a
taumodifiersastherapeutictargetsforalzheimersdisease
‡A
Tau modifiers as therapeutic targets for Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
tauphosphorylationandassembly
‡A
Tau phosphorylation and assembly.
‡9
1
|
919
|
|
|
‡a
tauphosphorylationinalzheimersdiseasepathogenorprotector
‡A
Tau phosphorylation in Alzheimer's disease: pathogen or protector?
‡9
1
|
919
|
|
|
‡a
telomeresandtelomeraseinalzheimersdiseaseepiphenomenaoranewfocusfortherapeuticstrategy
‡A
Telomeres and telomerase in Alzheimer's disease: epiphenomena or a new focus for therapeutic strategy?
‡9
1
|
919
|
|
|
‡a
temporalprimacyofoxidativestressinthepathologicalcascadeofalzheimerdisease
‡A
Temporal Primacy of Oxidative Stress in the Pathological Cascade of Alzheimer Disease
‡9
1
|
919
|
|
|
‡a
applicationofmicroarraytechnologytoneuropathologycuttingedgetoolwithclinicaldiagnosticspotentialortoomuchinformation
‡A
The application of microarray technology to neuropathology: cutting edge tool with clinical diagnostics potential or too much information?
‡9
1
|
919
|
|
|
‡a
bloodbrainbarrierinalzheimersdiseasenoveltherapeutictargetsandnanodrugdelivery
‡A
The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery
‡9
1
|
919
|
|
|
‡a
cellcycleandhormonalfluxesinalzheimerdiseaseanoveltherapeutictarget
‡A
The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target
‡9
1
|
919
|
|
|
‡a
cellcyclehypothesisofalzheimersdiseasesuggestionsfordrugdevelopment
‡A
The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development
‡9
1
|
919
|
|
|
‡a
cellcycleinalzheimerdiseaseauniquetargetforneuropharmacology
‡A
The cell cycle in Alzheimer disease: a unique target for neuropharmacology
‡9
1
|
919
|
|
|
‡a
cellcycleregulatorphosphorylatedretinoblastomaproteinisassociatedwithtaupathologyinseveraltauopathies
‡A
The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies
‡9
1
|
919
|
|
|
‡a
contributionofluteinizinghormonetoalzheimerdiseasepathogenesis
‡A
The contribution of luteinizing hormone to Alzheimer disease pathogenesis
‡9
1
|
919
|
|
|
‡a
downssideofmitochondria
‡A
The "Down's" side of mitochondria
‡9
1
|
919
|
|
|
‡a
earlieststageofcognitiveimpairmentintransitionfromnormalagingtoalzheimerdiseaseismarkedbyprominentrnaoxidationinvulnerableneurons
‡A
The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons
‡9
1
|
919
|
|
|
‡a
effectofmglur2activationonsignaltransductionpathwaysandneuronalcellsurvival
‡A
The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival
‡9
1
|
919
|
|
|
‡a
essentialroleoferkin4oxo2nonenalmediatedcytotoxicityinshsy5yhumanneuroblastomacells
‡A
The essential role of ERK in 4-oxo-2-nonenal-mediated cytotoxicity in SH-SY5Y human neuroblastoma cells
‡9
1
|
919
|
|
|
‡a
estrogenmythpotentialuseofgonadotropinreleasinghormoneagonistsforthetreatmentofalzheimersdisease
‡A
The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
fallacyofamyloidandcognitioninalzheimersdisease
‡A
The fallacy of amyloid and cognition in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
gonadotropinconnectioninalzheimersdisease
‡A
The gonadotropin connection in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
keyroleofoxidativestressinalzheimersdisease
‡A
The Key Role of Oxidative Stress in Alzheimer's Disease
‡9
1
|
919
|
|
|
‡a
mitochondrialdynamicsofalzheimersdiseaseandparkinsonsdiseaseofferimportantopportunitiesfortherapeuticintervention
‡A
The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention
‡9
1
|
919
|
|
|
‡a
neuronalexpressionofmyccausesaneurodegenerativephenotypeinanoveltransgenicmouse
‡A
The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse
‡9
1
|
919
|
|
|
‡a
neuroprotectiveactivitiesofmelatoninagainstthealzheimerbetaproteinarenotmediatedbymelatoninmembranereceptors
‡A
The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors
‡9
1
|
919
|
|
|
‡a
p38pathwayisactivatedinpickdiseaseandprogressivesupranuclearpalsyamechanisticlinkbetweenmitogenicpathwaysoxidativestressandtau
‡A
The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau.
‡9
1
|
919
|
|
|
‡a
potentialapplicationofantioxidantagentsinalzheimerdiseasetherapeutics
‡A
The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics
‡9
1
|
919
|
|
|
‡a
roleofabnormalmitochondrialdynamicsinthepathogenesisofalzheimersdisease
‡A
The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
roleofe2f1inthedevelopmentofhypertrophiccardiomyopathy
‡A
The role of E2F1 in the development of hypertrophic cardiomyopathy
‡9
1
|
919
|
|
|
‡a
roleofironandcopperintheaetiologyofneurodegenerativedisorderstherapeuticimplications
‡A
The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications
‡9
1
|
919
|
|
|
‡a
roleofmitogenactivatedproteinkinasepathwaysinalzheimersdisease
‡A
The role of mitogen-activated protein kinase pathways in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
roleofnovelchitinlikepolysaccharidesinalzheimerdisease
‡A
The role of novel chitin-like polysaccharides in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
roleofoxidativestressinthepathophysiologyofcerebrovascularlesionsinalzheimersdisease
‡A
The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
sirtuinpathwayinageingandalzheimerdiseasemechanisticandtherapeuticconsiderations
‡A
The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations
‡9
1
|
919
|
|
|
‡a
stateversusamyloidbetathetrialofthemostwantedcriminalinalzheimerdisease
‡A
The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
1balancebetweenmetabolicandoxidativeabnormalitiesandcellularcompensatoryresponsesinalzheimerdisease
‡A
The (un)balance between metabolic and oxidative abnormalities and cellular compensatory responses in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
upregulationofbace1mediatedbyhypoxiaandischemicinjuryroleofoxidativestressandhif1 Alpha
‡A
The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1 Alpha
‡9
1
|
919
|
|
|
‡a
10chromosomeinstabilityphenotypeinalzheimersdiseaseaclinicalsignofacceleratingaging
‡A
The X-chromosome instability phenotype in Alzheimer's disease: a clinical sign of accelerating aging?
‡9
1
|
919
|
|
|
‡a
therapeuticopportunitiesinalzheimerdisease1forallorallfor1
‡A
Therapeutic opportunities in Alzheimer disease: one for all or all for one?
‡9
1
|
919
|
|
|
‡a
therapeuticoptionsinalzheimersdisease
‡A
Therapeutic options in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
therapeuticpotentialof100mycinhibitioninthetreatmentofhypertrophiccardiomyopathy
‡A
Therapeutic potential of c-Myc inhibition in the treatment of hypertrophic cardiomyopathy
‡9
1
|
919
|
|
|
‡a
therapeuticpotentialofoxidantmechanismsinalzheimersdisease
‡A
Therapeutic potential of oxidant mechanisms in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
thinkingoutsidetheboxinalzheimerdiseasetreatment
‡A
Thinking Outside the Box in Alzheimer Disease Treatment
‡9
1
|
919
|
|
|
‡a
3dimensionaltomographicimagingandcharacterizationofironcompoundswithinalzheimersplaquecorematerial
‡A
Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material
‡9
1
|
919
|
|
|
‡a
3histidineresiduesofamyloidbetapeptidecontroltheredoxactivityofcopperandiron
‡A
Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron
‡9
1
|
919
|
|
|
‡a
tippingtheapoptoticbalanceinalzheimersdiseasetheabortosisconcept
‡A
Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept
‡9
1
|
919
|
|
|
‡a
transgenicmousemodelsofalzheimersdisease
‡A
Transgenic Mouse Models of Alzheimer's Disease
‡9
1
|
919
|
|
|
‡a
treatingthelesionsnotthedisease
‡A
Treating the lesions, not the disease
‡9
1
|
919
|
|
|
‡a
treatmentadvancesinalzheimersdiseasebasedontheoxidativestressmodel
‡A
Treatment advances in Alzheimer's disease based on the oxidative stress model
‡9
1
|
919
|
|
|
‡a
2hitsandyoureoutanovelmechanistichypothesisofalzheimerdisease
‡A
Two Hits and You’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease
‡9
1
|
919
|
|
|
‡a
upregulationofastrocytemetabotropicglutamatereceptor5byamyloidβpeptide
‡A
Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide
‡9
1
|
919
|
|
|
‡a
vascularoxidativestressinalzheimerdisease
‡A
Vascular oxidative stress in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
widespreaddistributionofreticulon3invariousneurodegenerativediseases
‡A
Widespread distribution of reticulon-3 in various neurodegenerative diseases
‡9
1
|
919
|
|
|
‡a
willpreventingproteinaggregatesliveuptoitspromiseasprophylaxisagainstneurodegenerativediseases
‡A
Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?
‡9
1
|
919
|
|
|
‡a
4oxo2nonenalisbothmoreneurotoxicandmoreproteinreactivethan4hydroxy2nonenal
‡A
4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal
‡9
1
|
919
|
|
|
‡a
clinicalstudyofluprondepotinthetreatmentofwomenwithalzheimersdiseasepreservationofcognitivefunctioninpatientstakinganacetylcholinesteraseinhibitorandtreatedwithhighdoselupronover48weeks
‡A
A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks
‡9
1
|
919
|
|
|
‡a
metabolicbasisforalzheimerdisease
‡A
A metabolic basis for Alzheimer disease
‡9
1
|
919
|
|
|
‡a
newmodelofoxidativestressinratpups
‡A
A new model of oxidative stress in rat pups
‡9
1
|
919
|
|
|
‡a
novelapproachtotheidentificationandquantitativeelementalanalysisofamyloiddepositsinsightsintothepathologyofalzheimersdisease
‡A
A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
novelendogenousindoleprotectsrodentmitochondriaandextendsrotiferlifespan
‡A
A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan
‡9
1
|
919
|
|
|
‡a
noveloriginforgranulovacuolardegenerationinagingandalzheimersdiseaseparallelstostressgranules
‡A
A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules
‡9
1
|
919
|
|
|
‡a
2lookintotheoxidantmechanismsinalzheimersdisease
‡A
A second look into the oxidant mechanisms in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
synergisticdysfunctionofmitochondrialfissionfusiondynamicsandmitophagyinalzheimersdisease
‡A
A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
aberrantexpressionofmetabotropicglutamatereceptor2inthevulnerableneuronsofalzheimersdisease
‡A
Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
aberrantlocalizationofimportin Alpha 1inhippocampalneuronsinalzheimerdisease
‡A
Aberrant localization of importin Alpha 1 in hippocampal neurons in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
abnormalironmetabolismandoxidativestressinmiceexpressingamutantformoftheferritinlightpolypeptidegene
‡A
Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene
‡9
1
|
919
|
|
|
‡a
abnormalmitochondrialdynamicsanoveltherapeutictargetforalzheimersdisease
‡A
Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?
‡9
1
|
919
|
|
|
‡a
abnormalmitochondrialdynamicsandneurodegenerativediseases
‡A
Abnormal mitochondrial dynamics and neurodegenerative diseases
‡9
1
|
919
|
|
|
‡a
abnormalmitochondrialdynamicsinthepathogenesisofalzheimersdisease
‡A
Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
absenceofcellularstressinbrainafterhypoxiainducedbyarousalfromhibernationinarcticgroundsquirrels
‡A
Absence of cellular stress in brain after hypoxia induced by arousal from hibernation in Arctic ground squirrels
‡9
1
|
919
|
|
|
‡a
accelerated Alpha synucleinaggregationafterdifferentiationofshsy5yneuroblastomacells
‡A
Accelerated Alpha -synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells
‡9
1
|
919
|
|
|
‡a
accumulationofintraneuronalamyloidβiscommoninnormalbrain
‡A
Accumulation of intraneuronal amyloid-β is common in normal brain.
‡9
1
|
919
|
|
|
‡a
activationofaktbylithiumprosurvivalpathwaysinaging
‡A
Activation of Akt by lithium: pro-survival pathways in aging
‡9
1
|
919
|
|
|
‡a
activationofp38kinaselinksπphosphorylationoxidativestressandcellcyclerelatedeventsinalzheimerdisease
‡A
Activation of P38 kinase links π phosphorylation, oxidative stress and cell cycle-related events in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
activationoftheextracellularsignalregulatedkinasepathwaycontributestothebehavioraldeficitoffragile10syndrome
‡A
Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome
‡9
1
|
919
|
|
|
‡a
adventiouslyboundredoxactiveironandcopperareatthecenterofoxidativedamageinalzheimerdisease
‡A
Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
agesragecomplexupregulatesbace1vianfκbpathwayactivation
‡A
AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation
‡9
1
|
919
|
|
|
‡a
alltransretinoicacidasanoveltherapeuticstrategyforalzheimersdisease
‡A
All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
alteredredoxbalanceindiseasecanwechangethenewequilibria
‡A
Altered redox balance in disease: Can we change the new equilibria?
‡9
1
|
919
|
|
|
‡a
alzheimerdiseaseandtheroleoffreeradicalsinthepathogenesisofthedisease
‡A
Alzheimer disease and the role of free radicals in the pathogenesis of the disease
‡9
1
|
919
|
|
|
‡a
alzheimerdiseaseevidenceforacentralpathogenicroleofironmediatedreactiveoxygenspecies
‡A
Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species
‡9
1
|
919
|
|
|
‡a
alzheimerdiseaseoxidativestressandcompensatoryresponses
‡A
Alzheimer Disease: Oxidative Stress and Compensatory Responses
‡9
1
|
919
|
|
|
‡a
alzheimerdiseasepathologyasahostresponse
‡A
Alzheimer disease pathology as a host response
‡9
1
|
919
|
|
|
‡a
alzheimerdiseasethe2hithypothesisanupdate
‡A
Alzheimer disease, the two-hit hypothesis: an update
‡9
1
|
919
|
|
|
‡a
alzheimerspecificepitopesoftaurepresentlipidperoxidationinducedconformations
‡A
Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations
‡9
1
|
919
|
|
|
‡a
alzheimersdiseaseadvancesforanewcentury
‡A
Alzheimer's Disease: Advances for a New Century
‡9
1
|
919
|
|
|
‡a
alzheimersdiseaseanintracellularmovementdisorder
‡A
Alzheimer's disease: an intracellular movement disorder?
‡9
1
|
919
|
|
|
‡a
alzheimersdiseaseandoxidativestresstheoldproblemremainsunsolved
‡A
Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
‡9
1
|
919
|
|
|
‡a
alzheimersdiseaseandthecellcycle
‡A
Alzheimer's disease and the cell cycle
‡9
1
|
919
|
|
|
‡a
alzheimersdiseasecerebrovasculardysfunctionoxidativestressandadvancedclinicaltherapies
‡A
Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies
‡9
1
|
919
|
|
|
‡a
alzheimersdiseasediverseaspectsofmitochondrialmalfunctioning
‡A
Alzheimer's disease: diverse aspects of mitochondrial malfunctioning
‡9
1
|
919
|
|
|
‡a
alzheimersdiseasethe2hithypothesis
‡A
Alzheimer's disease: the two-hit hypothesis
‡9
1
|
919
|
|
|
‡a
amyloidbetaa
‡A
Amyloid-beta: a
‡9
1
|
919
|
|
|
‡a
amyloidbetaalifepreserverforthebrain
‡A
Amyloid-beta: a (life) preserver for the brain
‡9
1
|
919
|
|
|
‡a
amyloidbetaavascularsealantthatprotectsagainsthemorrhage
‡A
Amyloid-beta: a vascular sealant that protects against hemorrhage?
‡9
1
|
919
|
|
|
‡a
amyloidbetaandtauserveantioxidantfunctionsintheagingandalzheimerbrain
‡A
Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain
‡9
1
|
919
|
|
|
‡a
amyloidbetaderiveddiffusibleligandscauseimpairedaxonaltransportofmitochondriainneurons
‡A
Amyloid-beta-derived diffusible ligands cause impaired axonal transport of mitochondria in neurons
‡9
1
|
919
|
|
|
‡a
amyloidbetainalzheimersdiseasethehorseorthecartpathogenicorprotective
‡A
Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?
‡9
1
|
919
|
|
|
‡a
amyloidbetainducedtoxicityofprimaryneuronsisdependentupondifferentiationassociatedincreasesintauandcyclindependentkinase5expression
‡A
Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression.
‡9
1
|
919
|
|
|
‡a
amyloidbetataualterationsandmitochondrialdysfunctioninalzheimerdiseasethechickensortheeggs
‡A
Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs?
‡9
1
|
919
|
|
|
‡a
amyloidbetathealternatehypothesis
‡A
Amyloid beta: the alternate hypothesis
‡9
1
|
919
|
|
|
‡a
amyloidbetavaccinationtestingtheamyloidhypothesisheadswewintailsyoulose
‡A
Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!
‡9
1
|
919
|
|
|
‡a
amyloidbeta42interactsmainlywithinsolubleprionproteininthealzheimerbrain
‡A
Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain
‡9
1
|
919
|
|
|
‡a
amyloidβ42interactsmainlywithinsolubleprionproteininthealzheimerbrain
‡A
Amyloid-β42 Interacts Mainly with Insoluble Prion Protein in the Alzheimer Brain
‡9
1
|
919
|
|
|
‡a
amyloidsaggregatesandneuronalinclusionsgoodorbadnewsforneurons
‡A
Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?
‡9
1
|
919
|
|
|
‡a
amyotrophiclateralsclerosisanovelhypothesisinvolvingagainedlossoffunctioninthejnksapkpathway
‡A
Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway
‡9
1
|
919
|
|
|
‡a
antibodiestopotatovirusybindtheamyloidbetapeptideimmunohistochemicalandnmrstudies
‡A
Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies
‡9
1
|
919
|
|
|
‡a
antigenantibodydissociationinalzheimerdiseaseanovelapproachtodiagnosis
‡A
Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis
‡9
1
|
919
|
|
|
‡a
antigonadotropinsanovelstrategytohaltalzheimersdiseaseprogression
‡A
Antigonadotropins: a novel strategy to halt Alzheimer's disease progression
‡9
1
|
919
|
|
|
‡a
antimicrobialpeptideβdefensin1expressionisupregulatedinalzheimersbrain
‡A
Antimicrobial peptide β-defensin-1 expression is upregulated in Alzheimer's brain
‡9
1
|
919
|
|
|
‡a
antioxidantapproachesforthetreatmentofalzheimersdisease
‡A
Antioxidant approaches for the treatment of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
antioxidantprotectionandneurodegenerativediseasetheroleofamyloidbetaandtau
‡A
Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau.
‡9
1
|
919
|
|
|
‡a
antioxidanttherapyinalzheimersdiseasetheoryandpractice
‡A
Antioxidant therapy in Alzheimer's disease: theory and practice
‡9
1
|
919
|
|
|
‡a
apoptosisinalzheimerdiseaseamathematicalimprobability
‡A
Apoptosis in Alzheimer disease: a mathematical improbability
‡9
1
|
919
|
|
|
‡a
apoptoticandoxidativeindicatorsinalzheimersdisease
‡A
Apoptotic and Oxidative Indicators in Alzheimer's Disease
‡9
1
|
919
|
|
|
‡a
apoptoticpromotersandinhibitorsinalzheimersdiseasewhowinsout
‡A
Apoptotic promoters and inhibitors in Alzheimer's disease: Who wins out?
‡9
1
|
919
|
|
|
‡a
ascorbatedistributionduringhibernationisindependentofascorbateredoxstate
‡A
Ascorbate distribution during hibernation is independent of ascorbate redox state
‡9
1
|
919
|
|
|
‡a
assemblyinvitrooftauproteinanditsimplicationsinalzheimersdisease
‡A
Assembly in vitro of tau protein and its implications in Alzheimer's disease.
‡9
1
|
919
|
|
|
‡a
atheroscleroticlesionsandmitochondriadnadeletionsinbrainmicrovesselsimplicationinthepathogenesisofalzheimersdisease
‡A
Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
autophagocytosisofmitochondriaisprominentinalzheimerdisease
‡A
Autophagocytosis of mitochondria is prominent in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
autophagyinalzheimersdisease
‡A
Autophagy in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
beyondestrogentargetinggonadotropinhormonesinthetreatmentofalzheimersdisease
‡A
Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
biomarkersinalzheimersdiseasepastpresentandfuture
‡A
Biomarkers in Alzheimer's disease: past, present and future
‡9
1
|
919
|
|
|
‡a
brca1maymodulateneuronalcellcyclereentryinalzheimerdisease
‡A
BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
100junphosphorylationinalzheimerdisease
‡A
c-Jun phosphorylation in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
callforelantopublishalzheimerstrialdetails
‡A
Call for Elan to publish Alzheimer's trial details.
‡9
1
|
919
|
|
|
‡a
carnosineaversatileantioxidantandantiglycatingagent
‡A
Carnosine: a versatile antioxidant and antiglycating agent
‡9
1
|
919
|
|
|
‡a
causesversuseffectstheincreasingcomplexitiesofalzheimersdiseasepathogenesis
‡A
Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis
‡9
1
|
919
|
|
|
‡a
cd3inlewypathologydoestheabnormalrecallofneurodevelopmentalprocessesunderlieparkinsonsdisease
‡A
CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease
‡9
1
|
919
|
|
|
‡a
cdk5isamajorregulatorofp38cascaderelevancetoneurotoxicityinalzheimersdisease
‡A
Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
cellcyclederegulationintheneuronsofalzheimersdisease
‡A
Cell cycle deregulation in the neurons of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
cellcycleproteinsinalzheimersdiseaseplentyofwheelsbutnocycle
‡A
Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle.
‡9
1
|
919
|
|
|
‡a
cellcyclereentryandmitochondrialdefectsinmycmediatedhypertrophiccardiomyopathyandheartfailure
‡A
Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure
‡9
1
|
919
|
|
|
‡a
cellcyclereentrymediatedneurodegenerationanditstreatmentroleinthepathogenesisofalzheimersdisease
‡A
Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
cellularprionproteinisessentialforoligomericamyloidβinducedneuronalcelldeath
‡A
Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death
‡9
1
|
919
|
|
|
‡a
cerebralamyloidangiopathymajorcontributorordecorativeresponsetoalzheimersdiseasepathogenesis
‡A
Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis
‡9
1
|
919
|
|
|
‡a
cerebralhemorrhageandamyloidbeta
‡A
Cerebral hemorrhage and amyloid-beta
‡9
1
|
919
|
|
|
‡a
cerebrotendinousxanthomatosiscasereportwithevidenceofoxidativestress
‡A
Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress
‡9
1
|
919
|
|
|
‡a
challengingtheamyloidcascadehypothesissenileplaquesandamyloidbetaasprotectiveadaptationstoalzheimerdisease
‡A
Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease
‡9
1
|
919
|
|
|
‡a
chapter19targetingoxidativemechanismsinalzheimerdisease
‡A
Chapter 19. Targeting Oxidative Mechanisms in Alzheimer Disease
‡9
1
|
919
|
|
|
‡a
chapter5developmentofironchelatornanoparticleconjugatesaspotentialtherapeuticagentsforalzheimerdisease
‡A
Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease
‡9
1
|
919
|
|
|
‡a
chitinlikepolysaccharidesinalzheimersdiseasebrains
‡A
Chitin-like polysaccharides in Alzheimer's disease brains
‡9
1
|
919
|
|
|
‡a
cholesterolhomeostasismarkersarelocalizedtomousehippocampalpyramidalandgranulelayers
‡A
Cholesterol homeostasis markers are localized to mouse hippocampal pyramidal and granule layers
‡9
1
|
919
|
|
|
‡a
cholesteroloxidativestressandalzheimersdiseaseexpandingthehorizonsofpathogenesis
‡A
Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis
‡9
1
|
919
|
|
|
‡a
chronicantioxidanttherapyreducesoxidativestressinamousemodelofalzheimersdisease
‡A
Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
chronicleptinsupplementationamelioratespathologyandimprovescognitiveperformanceinatransgenicmousemodelofalzheimersdisease
‡A
Chronic Leptin Supplementation Ameliorates Pathology and Improves Cognitive Performance in a Transgenic Mouse Model of Alzheimer's Disease
‡9
1
|
919
|
|
|
‡a
chronicoxidativestresscausesincreasedtauphosphorylationinm17neuroblastomacells
‡A
Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells
‡9
1
|
919
|
|
|
‡a
chronologicalprimacyofoxidativestressinalzheimerdisease
‡A
Chronological primacy of oxidative stress in Alzheimer disease.
‡9
1
|
919
|
|
|
‡a
cleavageandconformationalchangesoftauproteinfollowphosphorylationduringalzheimersdisease
‡A
Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
clinicalbenefitandpreservationofflavonolsindarkchocolatemanufacturing
‡A
Clinical benefit and preservation of flavonols in dark chocolate manufacturing
‡9
1
|
919
|
|
|
‡a
clusterinupregulationfollowingsublethaloxidativestressandlipidperoxidationinhumanneuroblastomacells
‡A
Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells
‡9
1
|
919
|
|
|
‡a
commentaryceramideandcholesterolpossibleconnectionsbetweennormalagingofthebrainandalzheimersdiseasejusthypothesesormolecularpathwaystobeidentifiedbyclaudiocostantinirekha1000kkolasaniandluigipuglielli
‡A
Commentary: "Ceramide and cholesterol: possible connections between normal aging of the brain and Alzheimer's disease. Just hypotheses or molecular pathways to be identified?" by Claudio Costantini, Rekha M.K. Kolasani, and Luigi Puglielli.
‡9
1
|
919
|
|
|
‡a
comparativebiologyandpathologyofoxidativestressinalzheimerandotherneurodegenerativediseasesbeyonddamageandresponse
‡A
Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response
‡9
1
|
919
|
|
|
‡a
compensatoryresponsesinducedbyoxidativestressinalzheimerdisease
‡A
Compensatory responses induced by oxidative stress in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
contributionofredoxactiveironandcoppertooxidativedamageinalzheimerdisease
‡A
Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease
‡9
1
|
919
|
|
|
‡a
copperinducesapoptosisofneuroblastomacellsviaposttranslationalregulationoftheexpressionofbcl2familyproteinsandthetxmouseisabettermodelofhepaticthanbraincutoxicity
‡A
Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity
‡9
1
|
919
|
|
|
‡a
coppermediatesdityrosinecrosslinkingofalzheimersamyloidbeta
‡A
Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta
‡9
1
|
919
|
|
|
‡a
currentapproachesinthetreatmentofalzheimersdisease
‡A
Current approaches in the treatment of Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
declineinmitochondrialbioenergeticsunderliescentralinsulinresistanceinstreptozocininducedmodelofsporadicalzheimersdisease
‡A
Decline in mitochondrial bioenergetics underlies central insulin resistance in streptozocin-induced model of sporadic Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
dementiaandtestosteronelevelsinmen
‡A
Dementia and testosterone levels in men.
‡9
1
|
919
|
|
|
‡a
detectionandlocalizationofmarkersofoxidativestressbyinsitumethodsapplicationinthestudyofalzheimerdisease
‡A
Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease
‡9
1
|
919
|
|
|
‡a
differentialregulationofglutamatereceptorsinalzheimersdisease
‡A
Differential regulation of glutamate receptors in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
directandindirectrolesofcyclindependentkinase5asanupstreamregulatorinthe100junnh2terminalkinasecascaderelevancetoneurotoxicinsultsinalzheimersdisease
‡A
Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
dissociatedamyloidbetaantibodylevelsasaserumbiomarkerfortheprogressionofalzheimersdiseaseapopulationbasedstudy
‡A
Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study
‡9
1
|
919
|
|
|
‡a
dissociatedaβantibodylevelinnewlydiagnosedalzheimersdiseaseapopulationbasedstudy
‡A
Dissociated Aβ antibody level in newly diagnosed Alzheimer's disease: A population-based study
‡9
1
|
919
|
|
|
‡a
disturbanceinampactivatedproteinkinase
‡A
Disturbance in AMP-activated protein kinase
‡9
1
|
919
|
|
|
‡a
disturbanceinampactivatedproteinkinaseampksignalingpathwayinalzheimersdisease
‡A
Disturbance in AMP-activated protein kinase (AMPK) signaling pathway in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
divalentmetaltransporterironandparkinsonsdiseaseapathologicalrelationship
‡A
Divalent metal transporter, iron, and Parkinson's disease: a pathological relationship.
‡9
1
|
919
|
|
|
‡a
dlp1dependentmitochondrialfragmentationmediates1methyl4phenylpyridiniumtoxicityinneuronsimplicationsforparkinsonsdisease
‡A
DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease
‡9
1
|
919
|
|
|
‡a
dnadamageinducescdk2proteinlevelsandhistoneh2bphosphorylationinshsy5yneuroblastomacells
‡A
DNA damage induces cdk2 protein levels and histone H2B phosphorylation in SH-SY5Y neuroblastoma cells.
‡9
1
|
919
|
|
|
‡a
downregulationofaminolevulinatesynthasetheratelimitingenzymeforhemebiosynthesisinalzheimersdisease
‡A
Down-regulation of aminolevulinate synthase, the rate-limiting enzyme for heme biosynthesis in Alzheimer's disease
‡9
1
|
919
|
|
|
‡a
downregulationofserumgonadotropinsbutnotestrogenreplacementimprovescognitioninagedovariectomized3xtgadfemalemice
‡A
Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice
‡9
1
|
919
|
|
|
‡a
downregulationofserumgonadotropinsisaseffectiveasestrogenreplacementatimprovingmenopauseassociatedcognitivedeficits
‡A
Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits
‡9
1
|
946
|
|
|
‡a
b
‡9
1
|
947
|
|
|
‡a
US
‡9
1
|
996
|
|
|
‡2
ISNI|0000000369306107
|
996
|
|
|
‡2
DNB|1064907067
|
996
|
|
|
‡2
RERO|A016603644
|
996
|
|
|
‡2
PLWABN|9810543571905606
|
996
|
|
|
‡2
DNB|137068352
|
996
|
|
|
‡2
LC|no2016122970
|
996
|
|
|
‡2
LC|n 83163851
|
996
|
|
|
‡2
NUKAT|n 99001523
|
996
|
|
|
‡2
BIBSYS|4014214
|
996
|
|
|
‡2
LC|no2009192458
|
996
|
|
|
‡2
NUKAT|n 2006055658
|
996
|
|
|
‡2
LC|n 2004089966
|
996
|
|
|
‡2
NSK|000335263
|
996
|
|
|
‡2
NTA|338679057
|
996
|
|
|
‡2
ISNI|000000002567802X
|
996
|
|
|
‡2
BNF|14630383
|
996
|
|
|
‡2
LIH|LNB:B_u__b_R;=B7
|
996
|
|
|
‡2
BIBSYS|8052162
|
996
|
|
|
‡2
SIMACOB|28210275
|
996
|
|
|
‡2
CAOONL|ncf10055987
|
996
|
|
|
‡2
BIBSYS|13028297
|
996
|
|
|
‡2
LC|n 92806495
|
996
|
|
|
‡2
BIBSYS|8030187
|
996
|
|
|
‡2
PLWABN|9814302434005606
|
996
|
|
|
‡2
LC|n 82225400
|
996
|
|
|
‡2
ISNI|0000000123615540
|
996
|
|
|
‡2
BNF|15523297
|
996
|
|
|
‡2
LC|nb 97040039
|
996
|
|
|
‡2
BIBSYS|90799252
|
996
|
|
|
‡2
LC|no2023007759
|
996
|
|
|
‡2
NLA|000054717891
|
996
|
|
|
‡2
LC|nr2006009016
|
996
|
|
|
‡2
BNC|981058616446606706
|
996
|
|
|
‡2
NUKAT|n 2017182839
|
996
|
|
|
‡2
NDL|01161394
|
996
|
|
|
‡2
LC|n 87129323
|
996
|
|
|
‡2
BIBSYS|10022339
|
996
|
|
|
‡2
DNB|1082229725
|
996
|
|
|
‡2
NUKAT|n 94300935
|
996
|
|
|
‡2
DBC|87097969700594
|
996
|
|
|
‡2
LC|n 83041295
|
996
|
|
|
‡2
DNB|1043568972
|
996
|
|
|
‡2
SUDOC|196546559
|
996
|
|
|
‡2
LC|nb2001087414
|
996
|
|
|
‡2
ISNI|0000000024557234
|
996
|
|
|
‡2
NDL|01007223
|
996
|
|
|
‡2
ISNI|0000000035421308
|
996
|
|
|
‡2
LC|n 88254047
|
996
|
|
|
‡2
LC|no2021120206
|
996
|
|
|
‡2
PTBNP|106657
|
996
|
|
|
‡2
BAV|495_300126
|
996
|
|
|
‡2
PLWABN|9810631968305606
|
996
|
|
|
‡2
LC|nr 96020312
|
996
|
|
|
‡2
BNC|981058616445406706
|
996
|
|
|
‡2
NTA|358180287
|
996
|
|
|
‡2
LC|nb 98038558
|
996
|
|
|
‡2
BIBSYS|90576088
|
996
|
|
|
‡2
BNE|XX4775169
|
996
|
|
|
‡2
PTBNP|31558
|
996
|
|
|
‡2
LC|nb2013025955
|
996
|
|
|
‡2
BNF|13340794
|
996
|
|
|
‡2
ISNI|0000000512433417
|
996
|
|
|
‡2
RERO|A023068041
|
996
|
|
|
‡2
BIBSYS|90226720
|
996
|
|
|
‡2
CAOONL|ncf13690061
|
996
|
|
|
‡2
LC|no 98128170
|
996
|
|
|
‡2
ISNI|0000000081058933
|
996
|
|
|
‡2
ISNI|0000000117748734
|
996
|
|
|
‡2
NUKAT|n 2023167183
|
996
|
|
|
‡2
NII|DA05999469
|
996
|
|
|
‡2
ISNI|000000038395926X
|
996
|
|
|
‡2
ISNI|0000000024659038
|
996
|
|
|
‡2
NSK|000392475
|
996
|
|
|
‡2
NTA|40086178X
|
996
|
|
|
‡2
NTA|06939153X
|
996
|
|
|
‡2
RERO|A026407529
|
996
|
|
|
‡2
CAOONL|ncf11055213
|
996
|
|
|
‡2
NLR|RU NLR AUTH 7756974
|
996
|
|
|
‡2
ISNI|0000000063050559
|
996
|
|
|
‡2
BIBSYS|3040180
|
996
|
|
|
‡2
NKC|mub2010614091
|
996
|
|
|
‡2
ISNI|0000000048210518
|
996
|
|
|
‡2
SUDOC|08171534X
|
996
|
|
|
‡2
DNB|17402682X
|
996
|
|
|
‡2
ISNI|0000000384199813
|
996
|
|
|
‡2
BAV|495_54775
|
996
|
|
|
‡2
LC|n 84134871
|
996
|
|
|
‡2
ISNI|0000000443026227
|
996
|
|
|
‡2
LIH|LNB:B1Z,;=BE
|
996
|
|
|
‡2
NUKAT|n 2007096749
|
996
|
|
|
‡2
ISNI|0000000110717265
|
996
|
|
|
‡2
LC|n 2011046712
|
996
|
|
|
‡2
SUDOC|033521298
|
996
|
|
|
‡2
SUDOC|086814974
|
996
|
|
|
‡2
DNB|1293409065
|
996
|
|
|
‡2
CAOONL|ncf11312363
|
996
|
|
|
‡2
LC|n 85047893
|
996
|
|
|
‡2
SUDOC|087929384
|
996
|
|
|
‡2
BNF|12431403
|
996
|
|
|
‡2
ISNI|0000000416668814
|
996
|
|
|
‡2
BNCHL|10000000000000000113813
|
996
|
|
|
‡2
BNF|13597929
|
996
|
|
|
‡2
ISNI|0000000418396963
|
996
|
|
|
‡2
BNF|15558267
|
996
|
|
|
‡2
ISNI|0000000036822859
|
996
|
|
|
‡2
RERO|A025269234
|
996
|
|
|
‡2
DNB|1024602877
|
996
|
|
|
‡2
NKC|jx20100409007
|
996
|
|
|
‡2
SUDOC|188040110
|
996
|
|
|
‡2
NDL|00475270
|
996
|
|
|
‡2
BIBSYS|90862526
|
996
|
|
|
‡2
LC|no2016037191
|
996
|
|
|
‡2
RERO|A012405199
|
996
|
|
|
‡2
NUKAT|n 2005025213
|
996
|
|
|
‡2
NUKAT|n 2002048812
|
996
|
|
|
‡2
SUDOC|271808535
|
996
|
|
|
‡2
BNF|14228316
|
996
|
|
|
‡2
NTA|191682624
|
996
|
|
|
‡2
NDL|001103919
|
996
|
|
|
‡2
ISNI|0000000031461484
|
996
|
|
|
‡2
J9U|987007329438705171
|
996
|
|
|
‡2
SUDOC|26695975X
|
996
|
|
|
‡2
BIBSYS|98072671
|
996
|
|
|
‡2
SUDOC|11928507X
|
996
|
|
|
‡2
BIBSYS|7014427
|
996
|
|
|
‡2
LC|nb 99156730
|
996
|
|
|
‡2
SUDOC|113753969
|
996
|
|
|
‡2
LC|n 92071038
|
996
|
|
|
‡2
ISNI|0000000114036512
|
996
|
|
|
‡2
LC|no2015007017
|
996
|
|
|
‡2
NII|DA11855361
|
996
|
|
|
‡2
DNB|103546568X
|
996
|
|
|
‡2
BNF|12458347
|
996
|
|
|
‡2
J9U|987007426941805171
|
996
|
|
|
‡2
ISNI|0000000508263726
|
996
|
|
|
‡2
LC|nb2020003165
|
996
|
|
|
‡2
BNC|981058616444806706
|
996
|
|
|
‡2
LC|no2016168078
|
996
|
|
|
‡2
ISNI|0000000115860669
|
996
|
|
|
‡2
BIBSYS|90383626
|
996
|
|
|
‡2
SUDOC|059363223
|
996
|
|
|
‡2
NII|DA18322674
|
996
|
|
|
‡2
BIBSYS|90816453
|
996
|
|
|
‡2
BIBSYS|7055759
|
996
|
|
|
‡2
NII|DA0883114X
|
996
|
|
|
‡2
NII|DA03575020
|
996
|
|
|
‡2
LC|no2024136945
|
996
|
|
|
‡2
J9U|987007381334905171
|
996
|
|
|
‡2
BAV|495_316089
|
996
|
|
|
‡2
NII|DA07841024
|
996
|
|
|
‡2
RERO|A005712237
|
996
|
|
|
‡2
ISNI|0000000063624073
|
996
|
|
|
‡2
LC|nb2008012359
|
996
|
|
|
‡2
DNB|135506255
|
996
|
|
|
‡2
SUDOC|085939013
|
996
|
|
|
‡2
BNF|12017045
|
996
|
|
|
‡2
LIH|LNB:8LF;=_t__j_
|
996
|
|
|
‡2
CAOONL|ncf11499341
|
996
|
|
|
‡2
DNB|1137198567
|
996
|
|
|
‡2
BNC|981058616447106706
|
996
|
|
|
‡2
ISNI|0000000081601414
|
996
|
|
|
‡2
ISNI|0000000109016023
|
996
|
|
|
‡2
ISNI|0000000046267561
|
996
|
|
|
‡2
NTA|143930753
|
996
|
|
|
‡2
LC|no2017073270
|
996
|
|
|
‡2
BIBSYS|90652489
|
996
|
|
|
‡2
LC|no2005104158
|
996
|
|
|
‡2
LC|no2017154444
|
996
|
|
|
‡2
LC|n 2016023550
|
996
|
|
|
‡2
RERO|A013553352
|
996
|
|
|
‡2
LC|n 88630455
|
996
|
|
|
‡2
LC|no2013121510
|
996
|
|
|
‡2
DNB|173182453
|
996
|
|
|
‡2
ISNI|0000000052046319
|
996
|
|
|
‡2
ISNI|0000000498898612
|
996
|
|
|
‡2
CAOONL|ncf11312244
|
996
|
|
|
‡2
ISNI|0000000074331647
|
996
|
|
|
‡2
ISNI|0000000082498121
|
996
|
|
|
‡2
SUDOC|120114097
|
996
|
|
|
‡2
NUKAT|n 2012151345
|
996
|
|
|
‡2
ISNI|0000000384916042
|
996
|
|
|
‡2
CAOONL|ncf11196667
|
996
|
|
|
‡2
LC|no2006135732
|
996
|
|
|
‡2
BIBSYS|11026734
|
996
|
|
|
‡2
BIBSYS|99004446
|
996
|
|
|
‡2
DBC|87097919459314
|
996
|
|
|
‡2
BIBSYS|90700677
|
996
|
|
|
‡2
J9U|987007335711005171
|
996
|
|
|
‡2
LC|n 96090520
|
996
|
|
|
‡2
RERO|A009137220
|
996
|
|
|
‡2
RERO|A003204519
|
996
|
|
|
‡2
RERO|A003839679
|
996
|
|
|
‡2
SUDOC|25842981X
|
996
|
|
|
‡2
ISNI|0000000390740530
|
996
|
|
|
‡2
BIBSYS|11074594
|
996
|
|
|
‡2
ISNI|0000000384476796
|
996
|
|
|
‡2
LC|no 98004579
|
996
|
|
|
‡2
ISNI|0000000037108489
|
996
|
|
|
‡2
BIBSYS|90387478
|
996
|
|
|
‡2
ISNI|0000000026148485
|
996
|
|
|
‡2
NII|DA11258715
|
996
|
|
|
‡2
BIBSYS|90965281
|
996
|
|
|
‡2
CAOONL|ncf12097282
|
996
|
|
|
‡2
DNB|133069052
|
996
|
|
|
‡2
DNB|1161749853
|
996
|
|
|
‡2
BLBNB|000181406
|
996
|
|
|
‡2
VLACC|000046376
|
996
|
|
|
‡2
LC|n 88238165
|
996
|
|
|
‡2
NUKAT|n 2024062246
|
996
|
|
|
‡2
BIBSYS|10020233
|
996
|
|
|
‡2
LC|nb2021004251
|
996
|
|
|
‡2
ISNI|0000000085305364
|
996
|
|
|
‡2
CAOONL|ncf11160211
|
996
|
|
|
‡2
LC|n 93108326
|
996
|
|
|
‡2
LC|n 77004568
|
996
|
|
|
‡2
LC|n 80046200
|
996
|
|
|
‡2
RERO|A011042512
|
996
|
|
|
‡2
ISNI|0000000435023587
|
996
|
|
|
‡2
LC|n 2005182352
|
996
|
|
|
‡2
DNB|14204976X
|
996
|
|
|
‡2
ISNI|0000000068377972
|
996
|
|
|
‡2
NTA|175432147
|
996
|
|
|
‡2
LC|no 95052676
|
996
|
|
|
‡2
BNF|14635918
|
996
|
|
|
‡2
NUKAT|n 2005130959
|
996
|
|
|
‡2
BNF|15736984
|
996
|
|
|
‡2
ISNI|0000000038742422
|
996
|
|
|
‡2
NUKAT|n 01036583
|
996
|
|
|
‡2
LNB|LNC10-000031504
|
996
|
|
|
‡2
ISNI|000000003550850X
|
996
|
|
|
‡2
SUDOC|272537519
|
996
|
|
|
‡2
NKC|vse2007387330
|
996
|
|
|
‡2
J9U|987007331006905171
|
996
|
|
|
‡2
LC|n 94011533
|
996
|
|
|
‡2
LC|n 79111477
|
996
|
|
|
‡2
RERO|A003456942
|
996
|
|
|
‡2
BIBSYS|90629150
|
996
|
|
|
‡2
LC|no2015003925
|
996
|
|
|
‡2
SUDOC|151772487
|
996
|
|
|
‡2
ISNI|0000000509841145
|
996
|
|
|
‡2
NII|DA11692132
|
996
|
|
|
‡2
BNF|16951485
|
996
|
|
|
‡2
BIBSYS|90544727
|
996
|
|
|
‡2
DNB|124321488
|
996
|
|
|
‡2
ISNI|0000000072485896
|
996
|
|
|
‡2
ISNI|0000000051657177
|
996
|
|
|
‡2
NKC|xx0158680
|
996
|
|
|
‡2
RERO|A021963921
|
996
|
|
|
‡2
LNB|LNC10-000030284
|
996
|
|
|
‡2
NTA|303068973
|
997
|
|
|
‡a
1965 2010 lived 0815 1219
‡9
1
|
998
|
|
|
‡a
Smith
‡b
Mark A.
‡2
BNF|15021893
‡3
suggested
‡3
exact title: (1.00, 'signaltransductioninalzheimersdisease', 'signaltransductioninalzheimersdisease')
|
998
|
|
|
‡a
Smith, Mark A.
‡2
PLWABN|9810544659705606
‡3
viafid
‡3
exact title: (1.00, 'alzheimersdiseaseandthecellcycle', 'alzheimersdiseaseandthecellcycle')
|
998
|
|
|
‡a
Smith, Mark A.,
‡2
LC|n 2013031838
‡3
suggested
‡3
double date
|
998
|
|
|
‡a
Mark Smith
‡c
American novelist, born 1935
‡2
ISNI|0000000019415688
‡3
suggested
|
998
|
|
|
‡a
Smith, Mark
‡c
(Analyst)
‡2
ISNI|0000000019415688
‡3
suggested
|
998
|
|
|
‡a
Smith, Mark
‡2
ISNI|0000000019415688
‡3
suggested
|
998
|
|
|
‡a
Smith, Mark
‡c
politologue
‡2
ISNI|0000000019415688
‡3
suggested
|
998
|
|
|
‡a
Smith, Mark A.
‡2
NUKAT|n 2005130959
‡3
suggested
|